Koss Tamara, Bagheri Bita, Zeana Cosmina, Romagnoli Mario F, Grossman Marc E
Department of Dermatology, Columbia-Presbyterian Medical Center, New York, New York, USA.
J Am Acad Dermatol. 2002 Jun;46(6):945-7. doi: 10.1067/mjd.2002.120627.
Invasive aspergillosis is uncommon in immunocompetent hosts but is the second most common opportunistic fungal infection in immunocompromised patients. There has been a dramatic increase in the incidence of life-threatening aspergillosis during the past 2 decades, and the morbidity and mortality of these infections despite antifungal therapy remain unacceptably high. We describe a patient with amphotericin B-resistant Aspergillus flavus successfully treated with caspofungin, an agent belonging to a new class of antifungal drugs. Caspofungin shows great promise in the treatment of invasive aspergillosis.
侵袭性曲霉病在免疫功能正常的宿主中并不常见，但却是免疫功能低下患者中第二常见的机会性真菌感染。在过去20年中，危及生命的曲霉病发病率急剧上升，尽管进行了抗真菌治疗，这些感染的发病率和死亡率仍然高得令人无法接受。我们描述了一名对两性霉素B耐药的黄曲霉患者，用卡泊芬净成功治疗，卡泊芬净是一种新型抗真菌药物。卡泊芬净在侵袭性曲霉病的治疗中显示出巨大的前景。
